GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Triptorelin Pamoate

Criteria

IVF

Inclusion criteria:

• Women aged <43 years at the time of IVF treatment

Exclusion criteria:

• Preimplantation genetic diagnosis treatment

• Use of donor oocytes or donor embryos

• Hydrosalpinx shown on pelvic scanning and not surgically treated

• Women at risk of OHSS

FET

Inclusion criteria:

• Women aged <43 years at the time of IVF treatment

• Replacing early cleavage embryos or blastocysts after thawing

• FET in natural cycles

Exclusion criteria:

• Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient

• Preimplantation genetic diagnosis treatment

• Use of donor oocytes or donor embryos

• Hydrosalpinx shown on pelvic scanning and not surgically treated